JPRN-UMIN000050778招募中Unknown
JAPANESE PROSPECTIVE REAL WORLD REGISTRY OF CABOZANTINIB PLUS NIVOLUMABIN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA - JACUMET study
Kindai University School of Medicine0 个研究点目标入组 200 人开始时间: 2023年4月6日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Synchronous or metachronous (within 3 years) malignancies. 2)Surgery prior to initiation of cabozantinib + nivolumab combination therapy with incomplete wound healing or continued postoperative complications 3) Radiotherapy within 14 days before starting cabozantinib + nivolumab combination therapy. Must be fully recovered from radiotherapy
研究者
相似试验
招募中
Unknown
JAPANESE PROSPECTIVE REAL WORLD REGISTRY OF CABOZANTINIB PLUS NIVOLUMABIN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMAadvanced or metastatic renal cell carcinomaJPRN-UMIN000052855Kinki University50
已完成
不适用
JAPANESE PROSPECTIVE REAL WORLD REGISTRY OF NIVOLUMAB PLUS IPILIMUMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMA (ARCC) CATEGORIZED INTO IMDC INTERMEDIATE/POOR RISKS (J-ENCORE)ADVANCED OR METASTATIC RENAL CELL CARCINOMAJPRN-UMIN000036772Bristol-Myers Squibb K.K. Ono Pharmaceutical CO.,LTD.286
尚未招募
Unknown
Japanese National RegistryPKD(JRP)autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney diseaseJPRN-jRCT1030230618Muto Satoru1,100
招募中
不适用
Establishment of Japanese-originated comprehensive biomarker system for diagnosis and stratification of patients with various types of dementias based on multicenter alliance for brain biomarkers (MABB)Mild cognitive impairmentJPRN-UMIN000047214Japan Agency for Medical Research and Development240
招募中
不适用
J-REGISTER: Japanese REal-world data for treatment of afatinib (GIotrif) in first-line setting and Subsequent Therapies for patients with advanced EGFR mutation-positive lung adenocarcinomaJPRN-UMIN000044071ippon Boehringer Ingelheim Co., Ltd.1,000